BD (BDX) Q2 2026 earnings review
The 'New BD' Emerges: Flawless Capital Execution and Massive Margin Expansion
With the Life Sciences spin-off officially in the rearview mirror, the 'New BD' wasted no time executing its promised playbook. The company immediately deployed proceeds from the Waters transaction to launch a $2.0B accelerated share repurchase and retire $2.1B in debt, instantly derisking the balance sheet and boosting EPS. Operationally, the core medtech business is accelerating: continuing operations revenue grew 5.2% YoY (up from 3.5% last quarter). But the real story is profitability. The 'BD Excellence' operating model drove absolute Cost of Goods Sold down 2.3% despite a 5.2% jump in sales, leading to a massive ~420 basis point gross margin expansion. Management subsequently raised FY26 adjusted EPS guidance. While a $450M non-cash asset impairment crushed GAAP earnings, the underlying cash engine is roaring, with YTD operating cash flow up 171%.
🐂 Bull Case
BD delivered exactly what was promised post-spin: deploying roughly $4.1B directly into shareholder value creation ($2.0B buybacks, $2.1B debt paydown) in a single quarter.
Achieving 5.2% top-line growth while simultaneously reducing COGS by 2.3% YoY is a textbook example of manufacturing efficiency. The BD Excellence program is generating profound operating leverage.
🐻 Bear Case
The BioPharma unit remains the clear laggard, shrinking 1.8% on an FX-neutral basis. Until this segment digests its inventory headwinds, it remains a drag on the broader portfolio.
International revenues declined 1.4% on an FX-neutral basis, likely reflecting persistent Volume-Based Procurement (VBP) pressures in China and softer European macro conditions.
⚖️ Verdict: 🟢
Bullish. BD successfully navigated a complex corporate spin-off and emerged with a cleaner portfolio, expanding margins, shrinking share count, and accelerating top-line growth. The raised guidance proves management's confidence.
Key Themes
Unprecedented Capital Return Execution
Following the spin-off of the Life Sciences business, BD received a massive cash distribution and immediately put it to work. In Q2 alone, the company executed a $2.0 billion Accelerated Share Repurchase (ASR) program and retired $2.1 billion of debt. This instantly alters the capital structure, significantly lowering interest expense burdens and reducing the share float, acting as a powerful mechanical driver for EPS acceleration through the rest of FY26.
BD Excellence Drives Surging Gross Margins
The most impressive operational metric of the quarter was the decoupling of revenue growth from cost of goods sold (COGS). While revenue rose 5.2% to $4.71B, COGS actually fell 2.3% to $2.56B. This resulted in gross margins surging from 41.5% a year ago to 45.7% in 26Q2. Management's long-touted 'BD Excellence' manufacturing and supply chain initiative is now delivering undeniable, flow-through profitability.
Interventional and Connected Care Lead the Charge
The top-line was carried by standout performances in specific sub-segments. Interventional segment revenues jumped 7.3% (5.3% FXN), propelled by an accelerating Surgery unit (+14.9% reported). Simultaneously, Connected Care grew 4.9%, heavily supported by Advanced Patient Monitoring, which spiked 13.6%. These high-acuity, technology-driven segments are successfully absorbing the growth burden.
BioPharma Systems Remanis the Problem Child
BioPharma Systems was the only segment to contract organically, falling 1.8% on a foreign currency-neutral basis to $590M. While management has previously pointed to GLP-1 delivery systems as a massive tailwind, the segment is clearly still fighting acute headwinds—likely ongoing normalization of legacy vaccine demand and broader bioprocessing destocking. It is the anchor dragging down overall Medical aggregate growth.
$450M Asset Impairment Clears the Deck
GAAP operating income collapsed 75.6% to just $93M due to a massive $533M charge for integration and restructuring. Buried in the footnotes is a $450M non-cash asset impairment charge related to exiting 'certain operational activities and projects which no longer align with... Excellence Unleashed.' While framed as a strategic cleanup, writing off nearly half a billion in property, plant, and intangibles indicates significant past capital misallocation.
International FX and Macro Pressures
While U.S. growth was a robust 5.1% across the board, International revenues declined 1.4% FXN (though they grew 5.5% on a reported basis due to favorable currency translation compared to previous periods). This structural volume weakness abroad highlights ongoing macro challenges, likely tied to China's Volume-Based Procurement (VBP) policies that management warned about in prior quarters.
Relentless Product Launch Cadence
Innovation velocity is visibly accelerating. Q2 saw the launch of the BD CentroVena One Insertion System, the Pyxis Pro Dispensing Solution in Europe, and the HemoSphere Stream Module for noninvasive blood pressure monitoring. Furthermore, earning three Best in KLAS awards for Pyxis and Alaris validates BD's technological moat in connected medication management.
Other KPIs
Accelerating dramatically. Cash provided by continuing operations over the first six months skyrocketed 171% from $489M in the prior year. This massive improvement in cash conversion is funding the aggressive capital return strategy without straining the balance sheet.
Sharply reversing. Following the Waters transaction, BD retired $2.1 billion of debt. Long-term debt plummeted from $17.6B at the end of FY25 to $14.7B, heavily reducing ongoing interest expense and freeing up future cash flows.
Increasing. SG&A rose 8.6% YoY in Q2, outpacing revenue growth of 5.2%. While gross margins are surging, management is clearly reinvesting a portion of those savings back into commercial and sales infrastructure to drive future top-line momentum.
Guidance
Accelerating. The company raised the range from the prior $12.35-$12.65. The new midpoint ($12.62) implies a 5.2% to 6.9% growth rate over the FY25 adjusted base ($11.90). This raise reflects the immediate accretive impact of the $2.0B share repurchase and strong Q2 operating margin execution.
Stable. The company maintained its core top-line outlook. With Q2 delivering 5.2% reported growth, this suggests management is maintaining a conservative posture for the second half of the year, likely baking in persistent international softness or lingering BioPharma headwinds.
Stable. The reiterated FXN guidance confirms that underlying volume and pricing assumptions remain unchanged despite the beat in Q2.
Key Questions
BioPharma Systems Turnaround
BioPharma was the only segment to contract organically (-1.8% FXN). Given the massive tailwinds from GLP-1 contracts touted in previous quarters, what is the specific timeline for this segment to return to durable, mid-single-digit growth?
Details on the $450M Impairment
The $450M non-cash impairment is a significant write-down. Which specific product lines, facilities, or R&D projects were abandoned as part of the 'Excellence Unleashed' alignment?
Future Capital Allocation Post-ASR
With the immediate $2.0B ASR completed and $2.1B in debt retired, what is the normalized run-rate for share repurchases and M&A for the remainder of FY26 and into FY27?